Exact Sciences Corporation (EXAS) Price Target Analysis

Updated Jun 18, 2026

Analyst Rating: Buy

Based on 41 analysts

0.1% Below Target

EXAS trades 0.1% below Wall Street's consensus target of $105.00.

Current Price$104.91

Average Target$105.00

Low$105.00

Median$105.00

High$105.00

Analyst Target Range

Forward P/E582.8x

(High Premium)

PEG Ratio—

Implied Growth+116.4%

(High Growth)

Analyst Spread0.0%

(High Agreement)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$104.91

Consensus$105.00

High$105.00

Low$105.00

Consensus Scenario Assumptions

The base valuation assumes EXAS achieves its forward estimates and maintains a stable P/E multiple of 582.8x. This scenario reflects the blended consensus of 41 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 41 published analyst recommendations for EXAS

41% hold / mixed conviction

BearishBullish

Weighted analyst sentiment score based on 41 ratings

ConsensusBuy

Coverage41 Analysts

Net Score+24

Bull / Bear54% / 5%

Strong Buy00%

Buy2254%

Hold1741%

Sell25%

Strong Sell00%

Strong Buy

00%

Buy

2254%

Hold

1741%

Sell

25%

Strong Sell

00%

Recommendation Mix54% Buy · 41% Hold · 5% Sell

Buy (22)Hold (17)Sell (2)

EXAS Price Target Analysis

Updated June 22, 2026

As of June 22, 2026, Exact Sciences Corporation (EXAS) has a Wall Street consensus price target of $105.00, based on estimates from 41 covering analysts. With the stock currently trading at $104.91, this represents a potential upside of +0.1%. The company has a market capitalization of $20.02B.

Analyst price targets range from a low of $105.00 to a high of $105.00, representing a 0% spread in expectations. The median target of $105.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.

The current analyst consensus rating is Buy, with 22 analysts rating the stock as a Buy or Strong Buy,17 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.

From a valuation perspective, EXAS trades at a trailing P/E of -95.4x and forward P/E of 582.8x. Analysts expect EPS to grow +116.4% over the next year.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis

Avg Peer Upside

+14.7%

Industry Consensus

Avg Forward P/E

23.4x

(Fair)

Peers with Coverage

10 / 10

Active Analyst Tracking

Company	Market Cap	Price	Target	Upside Potential	Rating	Fwd P/E	Analysts
GHGuardant Health, Inc.	$17.5B	$131.78	$147.00	+11.5%	Buy	—	30
NTRANatera, Inc.	$33.1B	$231.41	$259.88	+12.3%	Buy	—	27
ILMNIllumina, Inc.	$24.6B	$161.93	$151.40	-6.5%	Buy	31.0x	50
LHLabcorp Holdings Inc.	$21.1B	$255.82	$311.33	+21.7%	Buy	14.2x	35
DGXQuest Diagnostics Incorporated	$21.6B	$195.00	$220.57	+13.1%	Hold	18.1x	34
NEOGNeogen Corporation	$2.0B	$9.31	$11.00	+18.2%	Hold	25.2x	11
CDNACareDx, Inc	$1.4B	$26.18	$27.00	+3.1%	Buy	28.0x	13
TMOThermo Fisher Scientific Inc.	$172.7B	$464.61	$599.70	+29.1%	Buy	18.7x	42
DHRDanaher Corporation	$125.4B	$177.17	$230.89	+30.3%	Buy	21.0x	43
BIOBio-Rad Laboratories, Inc.	$7.6B	$282.44	$321.67	+13.9%	Buy	31.2x	14

EXAS — Frequently Asked Questions

Quick answers to the most common questions about buying EXAS stock.

What is the EXAS stock price target for 2026?

The consensus price target for EXAS is $105, close to the current price of $104.91 (0.1% implied move). Based on 41 analyst estimates, the stock appears fairly valued near current levels.

Is EXAS a buy, sell, or hold?

EXAS has a consensus rating of "Buy" based on 41 Wall Street analysts. The rating breakdown is predominantly bullish, with 22 Buy/Strong Buy ratings. The consensus 12-month price target of $105 implies 0.1% upside from current levels.

Is EXAS stock overvalued or undervalued?

At a forward P/E of 582.8333x, EXAS trades at a premium valuation. The consensus price target of $105 (0.1% upside) suggests analysts may view current valuations as stretched.

How high can EXAS stock go?

The most bullish Wall Street analyst has a price target of $105 for EXAS, while the most conservative target is $105. The consensus of $105 represents the median expectation. These targets typically reflect 12-month expectations.

How many analysts cover EXAS stock?

EXAS is heavily covered by Wall Street, with 41 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 22 have Buy ratings, 17 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the EXAS stock forecast?

The 12-month EXAS stock forecast based on 41 Wall Street analysts shows a consensus price target of $105, with estimates ranging from $105 (bear case) to $105 (bull case). The median consensus rating is "Buy".

What is EXAS's forward P/E ratio?

EXAS trades at a forward P/E ratio of 582.8x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy EXAS stock?

EXAS appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $105 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do EXAS price targets vary so much?

EXAS analyst price targets range from $105 to $105, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $105 consensus represents the middle ground.

Consensus-Based Analysis Tools